E
BLUE

Ergoteles’s bluebird bio BLUE Stock Holding History

Ergoteles’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,174
Closed -$162K – 1282
2022
Q4 		$162K Buy
+1,174
New +$165K 0.01% 1128
2022
Q3 		– Sell
-19,315
Closed -$1.6M – 1563
2022
Q2 		$1.6M Buy
19,315
+15,475
+403% +$1.2M 0.05% 374
2022
Q1 		$372K Buy
3,840
+2,776
+261% +$366K 0.01% 775
2021
Q4 		$213K Buy
+1,064
New +$251K 0.01% 1001
2021
Q2 		– Sell
-9,945
Closed -$3.88M – 1499
2021
Q1 		$3.88M Buy
+9,945
New +$4.9M 0.12% 199

Other funds holding BLUE

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ergoteles's BLUE Position: Q1 2023 in Review

Ergoteles sold out of bluebird bio (BLUE) in Q1 2023, closing a stake of 1,174 shares — an estimated $162K sold.

Ergoteles first reported a position in BLUE in Q1 2021 and held it in 5 quarters. The position peaked at $3.88M in Q1 2021. 177 funds tracked by Wall St. Rank hold BLUE as of Q1 2023.

  • Ergoteles reported no remaining bluebird bio position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 1,174 bluebird bio shares in Q1 2023, an estimated $162K.
  • Ergoteles first reported a position in bluebird bio in Q1 2021 and held it in 5 quarters.
  • Ergoteles's bluebird bio position peaked at $3.88M in Q1 2021.
  • 177 funds tracked by Wall St. Rank held bluebird bio as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.